EyePoint Pharmaceuticals, Duravyu and Diabetic Retinopathy
EyePoint reports midstage trial fail for Duravyu, raising serious questions about the prospect
Targeting a major pharmaceutical market in retinal diseases, EyePoint Pharmaceuticals has revealed that its lead drug candidate failed to meet its endpoint in a phase 2 trial. | Targeting a major pharmaceutical market in retinal diseases,
Joslin Diabetes Center investigators’ study finds discrepancies between participants’ eye health status and their ...
DS, enables autonomous diabetic retinopathy screening using handheld cameras, revolutionizing eye care accessibility and ...
Despite EyePoint Pharmaceuticals' NPDR endpoint miss, potential exists with 12-month phase 2 PAVIA data. Read why I think ...
At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network and the ...
Optomed USA, Inc., a medical technology company, introduces the Optomed Aurora AEYE, a handheld AI fundus camera that ...
Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today ...
AEYE Health, the leading company for AI retinal imaging and diagnostics, is thrilled to announce that it received the first ...
Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a provider of healthcare services in early detection of certain critical health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback